Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open
Guidance update and earnings put Teva Pharmaceutical Industries in focus
Teva Pharmaceutical Industries (NYSE:TEVA) raised its 2026 revenue outlook and confirmed mid single digit revenue growth targets for 2027, alongside second quarter results that included a swing to a net loss and detailed product level commentary.
See our latest analysis for Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries shares have had a mixed few months around the latest guidance and earnings, with a 12.47% year to date share price return and a very large 1 year total shareholder return of 113.69% suggesting momentum has been strong over the longer run.
If Teva's update has you thinking about where growth and risk are shifting next in healthcare, it could be worth scanning a curated list of 42 healthcare AI stocks
After Teva Pharmaceutical Industries lifted its outlook yet reported a quarterly loss, the stock sits at a very different place than it did a year ago. Investors may be weighing whether establishing a position now makes more sense than waiting for a pullback.
Most Popular Narrative: 14.9% Undervalued
The most followed narrative values Teva Pharmaceutical Industries at $40.90 per share based on analyst assumptions, compared with the latest close at $34.81. This frames the current debate around upside versus risk.
The analysts have a consensus price target of $40.9 for Teva Pharmaceutical Industries based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $33.0.
Want to see what sits underneath that valuation gap for Teva Pharmaceutical Industries? The key drivers involve projected earnings, margins and the future multiple that analysts are incorporating. You may wish to explore which assumptions have the most weight in arriving at that fair value perspective.
The same narrative uses an 8.58% discount rate and a detailed earnings path to arrive at its $40.90 fair value. It concludes that the current price reflects trading below that estimate in the context of consensus expectations for future profit growth and margins. Result: Fair Value of $40.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Teva Pharmaceutical Industries still faces concentration risk in key branded drugs and a sizeable debt load that could constrain flexibility if operating conditions turn less favourable.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
Another View on Teva Pharmaceutical Industries Valuation
The first narrative sees Teva Pharmaceutical Industries as about 14.9% undervalued at $40.90. Yet our DCF model paints a very different picture, with a future cash flow value of $64.78 per share. That is a much larger gap. Which set of assumptions do you find more realistic?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With mixed signals around Teva Pharmaceutical Industries, how do you feel about the balance of risk and reward today? Take a closer look at the numbers, then decide where you stand by reviewing the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Teva Pharmaceutical Industries?
If Teva Pharmaceutical Industries has your attention today, do not stop there. Broadening your watchlist with well researched ideas can strengthen your overall portfolio decisions.
- Spot potential value opportunities early by checking companies that screen as screener containing 19 high quality undiscovered gems.
- Strengthen your downside protection by reviewing 78 resilient stocks with low risk scores that aim to keep overall risk in check.
- Focus on financial resilience by scanning the solid balance sheet and fundamentals stocks screener (49 results) when testing ideas against tougher conditions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com